No Data
No Data
Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results
Dyne Therapeutics Price Target Maintained With a $50.00/Share by Chardan Capital
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Promising Advancements and Strategic Positioning of Dyne Therapeutics' DYNE-251: A Buy Rating Analysis
Piper Sandler Sticks to Their Buy Rating for Dyne Therapeutics (DYN)
Express News | Reported Earlier, Dyne Therapeutics Phase 1/2 Trial Update Highlights Sustained Functional Improvement In Duchenne Muscular Dystrophy With Exon 51-Skipping Candidate; Regulatory Submission Targeted For Early 2026